Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-cash Items (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Non-cash Items data on record, last reported at $66.2 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 22.31% year-over-year to $66.2 million; the TTM value through Sep 2025 reached $66.2 million, up 22.31%, while the annual FY2024 figure was $6.6 million, 472.78% up from the prior year.
  • Non-cash Items reached $66.2 million in Q3 2025 per COLL's latest filing, down from $76.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $82.4 million in Q1 2025 and bottomed at $6.1 million in Q4 2021.
  • Average Non-cash Items over 5 years is $47.3 million, with a median of $52.3 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: tumbled 53.35% in 2021, then soared 67.19% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $6.1 million in 2021, then surged by 31.02% to $8.0 million in 2022, then skyrocketed by 67.19% to $13.3 million in 2023, then tumbled by 50.11% to $6.6 million in 2024, then soared by 898.6% to $66.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $66.2 million in Q3 2025, $76.7 million in Q2 2025, and $82.4 million in Q1 2025.